The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer-related mortality in the United States. Because of the lack of viable treatment options for HCC, prevention in high-risk patients has been proposed as an alternative strategy. The main risk factor for HCC is cirrhosis and several lines of evidence implicate epidermal growth factor (EGF) in the progression of cirrhosis and development of HCC. We therefore examined the effects of the EGF receptor (EGFR) inhibitor erlotinib on liver fibrogenesis and hepatocellular transformation in three different animal models of progressive cirrhosis: a rat model induced by repeated, low-dose injections of diethylnitrosamine (DEN), a mouse model induced by carbon tetrachloride (CCl 4), and a rat model induced by bile duct ligation (BDL). Erlotinib reduced EGFR phosphorylation in hepatic stellate cells (HSC) and reduced the total number of activated HSC. Erlotinib also decreased hepatocyte proliferation and liver injury. Consistent with all these findings, pharmacological inhibition of EGFR signaling effectively prevented the progression of cirrhosis and regressed fibrosis in some animals. Moreover, by alleviating the underlying liver disease, erlotinib blocked the development of HCC and its therapeutic efficacy could be monitored with a previously reported gene expression signature predictive of HCC risk in human cirrhosis patients. Conclusion: These data suggest that EGFR inhibition using Food and Drug Administration-approved inhibitors provides a promising therapeutic approach for reduction of fibrogenesis and prevention of HCC in high-risk cirrhosis patients who can be identified and monitored by gene expression signatures. (HEPATOLOGY 2014;59:1577-1590)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Self-citationEndocytosis and intracellular trafficking of ErbBs
Sorkin, A., & Goh, L. K. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.029 · Cited by 756
Lupberger, J., Zeisel, M. B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C. J., Turek, M., Gorke, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2341 · Cited by 706
Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., Bonkovsky, H. L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.014 · Cited by 651
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Fibrosis-dependent mechanisms of hepatocarcinogenesis
Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444
Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois‐Mouthon, C., Rey, C., Clergue, F., Poupon, R., Barbu, V., & Rosmorduc, O. (2005) · Hepatology · doi:10.1002/hep.20538 · Cited by 340
The EGF receptor is required for efficient liver regeneration
Natarajan, A., Wagner, B., & Sibilia, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704126104 · Cited by 320
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Yang, C., Zeisberg, M., Mosterman, B., Sudhakar, A., Yerramalla, U., Holthaus, K., Xu, L., Eng, F., Afdhal, N., & Kalluri, R. (2003) · Gastroenterology · doi:10.1053/gast.2003.50012 · Cited by 282
Resistance to Carbon Tetrachloride-Induced Hepatotoxicity in Mice Which Lack CYP2E1 Expression
Wong, F. W.-Y., Chan, W.-Y., & Lee, S. S.-T. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8547 · Cited by 251
Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis
Hoshida, Y., Villanueva, A., Sangiovanni, A., Sole, M., Hur, C., Andersson, K. L., Chung, R. T., Gould, J., Kojima, K., Gupta, S., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.021 · Cited by 228
Self-citationTanabe, K. K., Lemoine, A., Finkelstein, D. M., Kawasaki, H., Fujii, T., Chung, R. T., Lauwers, G. Y., Kulu, Y., Muzikansky, A., Kuruppu, D., et al. (2008) · JAMA · doi:10.1001/jama.2007.65 · Cited by 207
Self-citationRole of CYP2E1 in Diethylnitrosamine-Induced Hepatocarcinogenesis In vivo
Kang, J. S., Wanibuchi, H., Morimura, K., Gonzalez, F. J., & Fukushima, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1369 · Cited by 203
Fujii, T., Fuchs, B. C., Yamada, S., Lauwers, G. Y., Kulu, Y., Goodwin, J. M., Lanuti, M., & Tanabe, K. K. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-79 · Cited by 202
Self-citationBlivet-Van Eggelpoël, M.-J., Chettouh, H., Fartoux, L., Aoudjehane, L., Barbu, V., Rey, C., Priam, S., Housset, C., Rosmorduc, O., & Desbois-Mouthon, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.019 · Cited by 181
Perugorria, M. J., Latasa, M. U., Nicou, A., Cartagena‐Lirola, H., Castillo, J., Goñi, S., Vespasiani‐Gentilucci, U., Zagami, M. G., Lotersztajn, S., Prieto, J., et al. (2008) · Hepatology · doi:10.1002/hep.22437 · Cited by 151
Chronic hepatitis: morphology and nomenclature.
Ishak, K. G. (1994) · PubMed · Cited by 151
The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Berasain, C., Perugorria, M. J., Latasa, M. U., Castillo, J., Goñi, S., Santamaría, M., Prìeto, J., & Avila, M. A. (2009) · Experimental Biology and Medicine · doi:10.3181/0901-mr-12 · Cited by 136
Expression of Epidermal Growth Factor and Its Receptor in Cirrhotic Liver Disease
Kömüves, L. G., Feren, A. M., Jones, A. L., & Fodor, E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004800610 · Cited by 95
Hoshida, Y., Fuchs, B. C., & Tanabe, K. K. (2012) · Current Cancer Drug Targets · doi:10.2174/15680096112091129 · Cited by 86
Self-citationToenjes, R. R., Löhler, J., Jf, O., Kay, G. F., Gh, S., Dalemans, W., Pavirani, A., & Paul, D. (1995) · PubMed · Cited by 56
Sommerfeld, A., Reinehr, R., & Häussinger, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005355 · Cited by 52
Cheng, J. C., Hsu, C.-Y., Hashem, S. A., & Dawson, L. A. (2012) · Springer eBooks · doi:10.1007/978-3-642-28860-9_16 · Cited by 44
Huang, G., Besner, G. E., & Brigstock, D. R. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.3 · Cited by 37
Kuriyama, S., Yokoyama, F., Inoue, H., Takano, J., Ogawa, M., Kita, Y., Yoshiji, H., Deguchi, A., Kimura, Y., Himoto, T., et al. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.2.317 · Cited by 20
Lee, T. Y., Kim, K., & Han, S. (2007) · PubMed · Cited by 17
Falleti, E., Cmet, S., Fabris, C., Bitetto, D., Cussigh, A., Fornasiere, E., Bignulin, E., Feruglio, C., Mosanghini, E., Fontanini, E., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.10.018 · Cited by 14
Cmet, S., Fabris, C., Fattovich, G., Falleti, E., Bitetto, D., Cussigh, A., Fontanini, E., Fornasiere, E., Pirisi, M., & Toniutto, P. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04497.x · Cited by 12
Cited by
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Self-citationRisk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Self-citationCancer biomarker discovery and validation.
Goossens, N., Nakagawa, S., Sun, X., & Hoshida, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-676x.2015.06.04 · Cited by 503
Self-citationSingle-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Self-citation
Metadata
- Authors
- Fuchs, B. C., Hoshida, Y., Fujii, T., Wei, L., Yamada, S., Lauwers, G. Y., McGinn, C. M., DePeralta, D. K., Chen, X., Kuroda, T., Lanuti, M., Schmitt, A. D., Gupta, S., Crenshaw, A., Onofrio, R., Taylor, B., Winckler, W., Bardeesy, N., Caravan, P., Golub, T. R., & Tanabe, K. K.
- Venue
- Hepatology
- Published
- 2014-04
- Volume
- 59
- Issue
- 4
- Pages
- 1577-1590
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2069076782
- Cited by
- 351
- References
- 38
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.